This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wielbo, D. Articles by Toffolo, S. Search for Related Content PubMed PubMed Citation Articles by Wielbo, D. Articles by Toffolo, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure

(Hypertension. 1996;28:147-151.)
© 1996 American Heart Association, Inc.

Articles

Inhibition of Hypertension by Peripheral Administration of Antisense Oligodeoxynucleotides

Donna Wielbo; Amy Simon; M. Ian Phillips; Shawn Toffolo

the Departments of Pharmaceutics and Physiology (M.I.P.), J. Hillis Miller Health Center, University of Florida, Gainesville.

Correspondence to Donna Wielbo, Department of Pharmaceutics, Box 100494, JHMHC, University of Florida, Gainesville, FL 32610-0494. E-mail wielbo@cop.health.ufl.edu.

We administered liposome-encapsulated antisense oligodeoxynucleotide targeted to angiotensinogen mRNA peripherally to spontaneously hypertensive rats to test whether peripheral angiotensinogen reduction would lower their hypertensive blood pressures and to determine the role of peripheral angiotensinogen in the modulation of hypertension. Using in vitro translation techniques, we tested the sequence specificity of the antisense sequence. The selected antisense sequence decreased angiotensinogen production in vitro, enabling us to distinguish between specific and nonspecific effects. To increase the efficiency of peripheral and hepatic antisense delivery, oligonucleotides were liposome encapsulated for intra-arterial administration. Confocal microscopy was used for determination of the hepatic distribution of fluorescently labeled antisense. Encapsulated antisense molecules were seen to be distributed within liver tissue 1 hour after injection; however, little or no uptake was observed with the unencapsulated oligonucleotides. We also determined the physiological effects of antisense oligodeoxynucleotide targeted to liver angiotensinogen mRNA. Administration of liposome-encapsulated antisense significantly decreased hypertensive blood pressures to normotensive levels compared with scrambled control oligonucleotides, unencapsulated antisense, and empty liposomes (P=.013). These data were supported by biochemical changes elicited by the antisense treatment. Rats receiving liposome-encapsulated antisense had significantly lowered peripheral angiotensinogen and angiotensin II levels compared with control groups (P<.05). No significant heart rate changes were observed in the antisense or control groups. These results suggest that peripheral angiotensinogen plays a role in the maintenance of hypertensive blood pressure in this model of hypertension and that peripheral administration of antisense molecules is possible with organ-targeted delivery mechanisms.

Key Words: angiotensinogen • antisense • hyper-tension, essential

This article has been cited by other articles:

				M. K. Raizada and S. D. Sarkissian Potential of Gene Therapy Strategy for the Treatment of Hypertension Hypertension, January 1, 2006; 47(1): 6 - 9. [Full Text] [PDF]

				Y. Zhang, K. K. Griendling, A. Dikalova, G. K. Owens, and W. R. Taylor Vascular Hypertrophy in Angiotensin II-Induced Hypertension Is Mediated by Vascular Smooth Muscle Cell-Derived H2O2 Hypertension, October 1, 2005; 46(4): 732 - 737. [Abstract] [Full Text] [PDF]

				M. I. Phillips Gene Therapy for Hypertension: The Preclinical Data Hypertension, September 1, 2001; 38(3): 543 - 548. [Abstract] [Full Text] [PDF]

				S. Kagiyama, A. Varela, M. I. Phillips, and S. M. Galli Antisense Inhibition of Brain Renin-Angiotensin System Decreased Blood Pressure in Chronic 2-Kidney, 1 Clip Hypertensive Rats Hypertension, February 1, 2001; 37(2): 371 - 375. [Abstract] [Full Text] [PDF]

				S. K. Klimuk, S. C. Semple, P. N. Nahirney, M. C. Mullen, C. F. Bennett, P. Scherrer, and M. J. Hope Enhanced Anti-Inflammatory Activity of a Liposomal Intercellular Adhesion Molecule-1 Antisense Oligodeoxynucleotide in an Acute Model of Contact Hypersensitivity J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 480 - 488. [Abstract] [Full Text]

				X. Tang, D. Mohuczy, Y. C. Zhang, B. Kimura, S. M. Galli, and M. I. Phillips Intravenous angiotensinogen antisense in AAV-based vector decreases hypertension Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2392 - H2399. [Abstract] [Full Text] [PDF]

				N. Makino, M. Sugano, S. Ohtsuka, S. Sawada, and T. Hata Chronic antisense therapy for angiotensinogen on cardiac hypertrophy in spontaneously hypertensive rats Cardiovasc Res, December 1, 1999; 44(3): 543 - 548. [Abstract] [Full Text] [PDF]

				T. Nishii, A. Moriguchi, R. Morishita, K. Yamada, S. Nakamura, N. Tomita, Y. Kaneda, A. Fukamizu, H. Mikami, J. Higaki, et al. Angiotensinogen Gene–Activating Elements Regulate Blood Pressure in the Brain Circ. Res., August 6, 1999; 85(3): 257 - 263. [Abstract] [Full Text] [PDF]

				D. P. Healy and L. Song Kidney Aminopeptidase A and Hypertension, Part I : Spontaneously Hypertensive Rats Hypertension, February 1, 1999; 33(2): 740 - 745. [Abstract] [Full Text] [PDF]

				M. I. Phillips Is Gene Therapy for Hypertension Possible? Hypertension, January 1, 1999; 33(1): 8 - 13. [Full Text] [PDF]

				B. C. Yang, M. I. Phillips, Y. C. Zhang, B. Kimura, L. P. Shen, P. Mehta, and J. L. Mehta Critical Role of AT1 Receptor Expression After Ischemia/Reperfusion in Isolated Rat Hearts : Beneficial Effect of Antisense Oligodeoxynucleotides Directed at AT1 Receptor mRNA Circ. Res., September 7, 1998; 83(5): 552 - 559. [Abstract] [Full Text] [PDF]

				B. Yang, D. Li, M I. Phillips, P. Mehta, and J. L Mehta Myocardial angiotensin II receptor expression and ischemia-reperfusion injury Vascular Medicine, May 1, 1998; 3(2): 121 - 130. [Abstract] [PDF]

				N. Makino, M. Sugano, S. Ohtsuka, and S. Sawada Intravenous Injection With Antisense Oligodeoxynucleotides Against Angiotensinogen Decreases Blood Pressure in Spontaneously Hypertensive Rats Hypertension, May 1, 1998; 31(5): 1166 - 1170. [Abstract] [Full Text] [PDF]

				P. Corvol and X. Jeunemaitre Molecular Genetics of Human Hypertension: Role of Angiotensinogen Endocr. Rev., October 1, 1997; 18(5): 662 - 677. [Abstract] [Full Text]

				D. Lu, M. K. Raizada, S. Iyer, P. Reaves, H. Yang, and M. J. Katovich Losartan Versus Gene Therapy : Chronic Control of High Blood Pressure in Spontaneously Hypertensive Rats Hypertension, September 1, 1997; 30(3): 363 - 370. [Abstract] [Full Text]

				M. I. Phillips Antisense Inhibition and Adeno-Associated Viral Vector Delivery for Reducing Hypertension Hypertension, January 1, 1997; 29(1): 177 - 187. [Abstract] [Full Text] [PDF]

				M. I. Phillips, D. Mohuczy-Dominiak, M. Coffey, S. M. Galli, B. Kimura, P. Wu, and T. Zelles Prolonged Reduction of High Blood Pressure With an In Vivo, Nonpathogenic, Adeno-Associated Viral Vector Delivery of AT1-R mRNA Antisense Hypertension, January 1, 1997; 29(1): 374 - 378. [Abstract] [Full Text] [PDF]